Akums Drugs & Pharmaceuticals Ltd Q1 FY27 Earnings Call: Guides Double-Digit Volume Growth, Oriflame Acquisition Opens Cosmeceuticals

Akums Drugs & Pharmaceuticals Ltd held its Q1 FY27 earnings call on August 08, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Solid top-line beat with margin expansion

• Rs.1,167 crores operating revenue — up 13.9% YoY in Q1 FY2026-2027, led by CDMO strength and early signs of API recovery.
• EBITDA of Rs.175 crores — grew 35.4% YoY, with margin of 15.0% expanding 230 bps YoY, aided by a favourable product mix and strategic inventory build in Q4 FY2025-2026.
• PAT of Rs.101 crores — rose 56.1% YoY, reflecting operating leverage and narrowing API losses.
• Operating cash flow of Rs.65 crores — generated in the quarter; balance sheet remains healthy with a net cash surplus of Rs.1,600 crores as of Q1 FY2026-2027.
• Gross margin improved 1.5% — driven by a shift to high-value products; management expects this level to be sustainable minus ~0.5% going forward.

High-teens momentum continues, cost-plus model intact

• CDMO revenue grew 18.6% YoY — to Rs.964 crores in Q1 FY2026-2027, with CDMO EBITDA of Rs.163 crores (+36.8% YoY) benefiting from improved capacity utilisation and a rebound in API prices.
• High-teens volume growth for three consecutive quarters — recorded in Q3 FY2025-2026, Q4 FY2025-2026, and Q1 FY2026-2027; Q2 FY2026-2027 is also expected to show strong high-teens growth.
• CDMO operates on a cost-plus model — Sahil Maheshwari confirmed that input material prices are passed through on each purchase order, insulating margins from raw-material inflation.
• Company volume growth outpaces IPM — management noted AKUMS growth is exceeding the Indian pharma market (IPM) volume growth of 2-3% plus new launches.
• Managed annual margin guidance of 14-15% — given Q1 FY2026-2027 strength, management expects the full year to incline towards the upper end of the band.

Domestic branded under pressure; trade generic at break-even

• Domestic branded formulation (Acumenitis) revenue of Rs.115 crores — up 7.3% YoY, but EBITDA fell 25.4% YoY (and 46.5% QoQ) to Rs.12 crores, impacted by a ~15% increase in field force headcount (200 people added in Q1 FY2026-2027).
• International branded formulation revenue of Rs.35 crores — declined 1.5% YoY; EBITDA of Rs.6.9 crores (-14.4% YoY). Management expects strong growth orders from Q2 FY2026-2027 onwards.
• Trade generic revenue of Rs.21 crores — down 9.5% YoY, but EBITDA remained at break-even for the second consecutive quarter.
• Current field force productivity (PCPM) below industry averages — management acknowledged this is expected during the business-building phase, with investments focused on clinical presence for power products and geographic expansion.
• Domestic branded margins expected to improve from Q3 FY2026-2027 — as new hires mature and prescription business in gynecology, cardiology, and pediatrics scales.

API losses narrowing; Zambia and Europe to lift margins

• API revenue of Rs.32 crores — fell 29.7% YoY, but EBITDA loss narrowed to -Rs.4 crores (from -Rs.6 crores in Q1 FY2025-2026 and -Rs.12 crores in Q4 FY2025-2026), driven by a higher share of non-CIPA products.
• API gross margins declined from 90%+ in FY2025-2026 to 75% in Q1 FY2026-2027 — which positively impacted overall corporate gross margins; management noted non-CDMO products (Lenalidomide, Montelukast) are improving margins.
• API business targeted to be monthly EBITDA-positive by end of FY2026-2027 (February/March) — Sahil Maheshwari guided that the segment should start contributing positively in FY2027-2028.
• Zambia business expected to deliver $25M (~Rs.240 crores) revenue in H2 FY2026-2027 — with EBITDA margins in the higher teens, similar to or slightly above the current CDMO business. Volumes and prices agreed with the government for 100+ products.
• European business expected to commence in FY2027-2028 — also targeting margins in the higher teens, set to further uplift corporate margins.

Oriflame acquisition opens cosmeceuticals; Baddi facility on track

• Acquisition of Oriflame India's manufacturing business announced on 23 Jul 2026 — covering two facilities in Roorkee and Noida, expanding into skincare, cosmetics, and wellness products.
• New capacity targets skincare cosmeceuticals and color cosmetics — leveraging Akums' formulation R&D expertise; no subcontracting is planned given gross margins above 40%.
• New oral manufacturing facility in Baddi expected to go live by end of FY2026-2027 — CAPEX details to be disclosed later; will support double-digit volume growth trajectory.
• Current capacity utilisation at ~50% — can increase to 55% with European and Zambian orders; management plans to maintain spare capacity to capture volume growth opportunities.
• No additional senior recruitment needed — management cited strong homegrown talent (M.Pharm, PhDs, doctorates) as sufficient to execute current growth plans.

Strong balance sheet, double-digit volume guidance for FY27

• Net cash of Rs.1,600 crores as of Q1 FY2026-2027 — 98% parked in fixed deposits with nationalized banks; net worth stands at over Rs.3,400 crores, providing ample "ammunition" for value-accretive acquisitions.
• Management guided for at least double-digit volume growth for FY2026-2027 — underpinned by sustained industry demand and capacity additions in oral tablets going live by end of FY2026-2027.
• Annual EBITDA margin guidance maintained at 14-15% — with Q1 FY2026-2027 at 15%, management expects the full year to incline towards the upper bracket.
• API business targeted to be monthly EBITDA-positive by February/March FY2026-2027 — and should start contributing positively in FY2027-2028.
• Management will remain cautious on large M&A bets — despite Rs.1,600 crores cash on hand, the company may explore acquisitions for business synergies but will avoid overpaying.